Insmed was one of the only bright spots in a brutal week for stocks — up 20.6% to $144.46 after reports that Sanofi is weighing a takeover. The stock ran as high as $149.07 and even tripped a volatility halt. With Insmed valued at $26.28 billion before the move, a standard 30–50% premium points to a $35–40 billion deal, and one analyst view implies $42.78 billion.
Nothing is signed — both companies declined to comment and any deal could still be weeks away. But Sanofi needs growth as Dupixent's patent clock ticks, and Brinsupri is scaling fast: $400.1 million in Q3, up 29% from Q2. I wrote up the full picture here: https://zimbuck.com/blogs/5804/Insmed-Shares-Jump-21-as-Sanofi-Weighs-a-Takeover-That
Do you think a deal gets done — or does the stock give back Thursday's gain?
Nothing is signed — both companies declined to comment and any deal could still be weeks away. But Sanofi needs growth as Dupixent's patent clock ticks, and Brinsupri is scaling fast: $400.1 million in Q3, up 29% from Q2. I wrote up the full picture here: https://zimbuck.com/blogs/5804/Insmed-Shares-Jump-21-as-Sanofi-Weighs-a-Takeover-That
Do you think a deal gets done — or does the stock give back Thursday's gain?
1 Views